Novozymes and
Chr. Hansen to combine
and create a leading global biosolutions partner
Key documents
Announcements
Notice convening the extraordinary general meeting 2024
Completion of the combination between Novozymes and Chr. Hansen
Retail brochure (in Danish only, January 2024)
All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen
Novozymes and Chr. Hansen announce name of future combined company
Conditional competition clearance from the European Commission obtained
Update on merger EC offered remedy proposal
Executive Leadership Team and organizational structure announced for the future combined company of Novozymes and Chr. Hansen
Stock exchange announcement regarding approval of combination by Novozymes shareholders
Investor news on the approval of combination by the Novozymes shareholders and Chr. Hansen shareholders
Press release on the approval of combination by the Novozymes shareholders and Chr. Hansen shareholders
Investor news on U.S. antitrust regulation
Investor news on Chinese merger approval
Stock exchange announcement regarding exemption document
Stock exchange announcement regarding proposed merger
Press release regarding proposed merger
Exemption document and related documents
Exemption document (for other jurisdictions than Australia)
Exemption document for shareholders of Chr. Hansen Holding A/S residing in Australia
Retail brochure (in Danish only, March 2023)
Merger documents
Merger plan
Merger statement
Tax-exempt merger ruling
Auditor documents
Valuer’s report on the merger plan
Valuer’s report on the creditors’ position after merger
Extraordinary shareholder’s meeting March 30, 2023
Notice convening the extraordinary general meeting
Live streaming of extraordinary shareholders’ meeting
Live streaming of extraordinary shareholders’ meeting (in Danish)
Resolutions from extraordinary shareholders’ meeting
Minutes from extraordinary shareholders’ meeting
Presentation
Investor presentation (December 12, 2022)
Conference call (December 12, 2022)
Other documents
Presentation of the Executive Leadership Team of the future combined company
Draft articles of association for Novozymes after completion of the Merger
Revised remuneration policy
Novozymes Remuneration Report 2022
Novozymes Articles of Association (March 30, 2023)
Novozymes annual reports
The Novozymes Annual Report 2022
The Novozymes Annual Report 2021
The Novozymes Annual Report 2020
The Novozymes Annual Report 2019
Chr. Hansen annual reports
The Chr. Hansen Annual Report 2021/2022
The Chr. Hansen Annual Report 2020/2021
The Chr. Hansen Annual Report 2019/2020
FAQ
Factsheet
Contacts
Investor relations
Tobias Cornelius Björklund
Head of Investor relations
+45 3077 8682
tobb@novozymes.com